# OnCo record paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009" ;
  schema:name "Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma"@en ;
  schema:description "IPASS randomised 1,217 East Asian never-smokers and light former smokers between a tablet and chemotherapy. The tablet won, but only in the patients whose tumour carried an EGFR mutation; in the rest chemotherapy was better."@en ;
  schema:url <https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa0810699>, <https://pubmed.ncbi.nlm.nih.gov/19692680/>, <https://clinicaltrials.gov/study/NCT00322452> ;
  onco:tag "lung-evidence" ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa0810699> ;
  schema:datePublished "2009"^^xsd:gYear ;
  schema:author "Mok TS, Wu YL, Thongprasert S, et al." ;
  onco:related <https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/>, <https://onco.cc/key-papers/paper-paez-egfr-mutations-gefitinib-science-2004/>, <https://onco.cc/key-papers/paper-egfr-nsclc-n-engl-j-med-2010/>, <https://onco.cc/key-papers/paper-egfr-nsclc-lancet-oncol-2012/>, <https://onco.cc/key-papers/paper-flaura-nejm-2018/> ;
  onco:cancers <https://onco.cc/cancers/lung-cancer/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/>, <https://onco.cc/cancers/lung-adenocarcinoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/terms/ngs/>, <https://onco.cc/terms/ihc/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/gefitinib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/> ;
  onco:terms <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/oncogene-addiction/>, <https://onco.cc/terms/histology/> ;
  onco:people <https://onco.cc/people/tony-mok/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-trial-design/> ;
  onco:journals <https://onco.cc/journals/nejm/> .